PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)

Proprotein convertase subtilisin/kexin type 9 (PCSK9), as a vital modulator of low-density lipoprotein cholesterol (LDL-C) , is raised in hepatocytes and released into plasma where it binds to LDL receptors (LDLR), leading to their cleavage. PCSK9 adheres to the epidermal growth factor-like repeat A...

Descripción completa

Detalles Bibliográficos
Autores principales: Sobati, Saeideh, Shakouri, Amir, Edalati, Mahdi, Mohammadnejad, Daryoush, Parvan, Reza, Masoumi, Javad, Abdolalizadeh, Jalal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539318/
https://www.ncbi.nlm.nih.gov/pubmed/33062601
http://dx.doi.org/10.34172/apb.2020.062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539318/
https://www.ncbi.nlm.nih.gov/pubmed/33062601
http://dx.doi.org/10.34172/apb.2020.062

Ejemplares similares